Marker Therapeutics, Inc.

Monthly Archives: May 2016

TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City

(TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at two financial conferences in New York City during the week of May 30 through June 3, 2016. The Company presentations will be made by Dr.

Read More